Engage Venture Partners

07/19/2023

Happy birthday to Engage! We had a busy first year powering medtech innovation. Amid a challenging early-stage funding environment, our investors backed six game-changing companies, providing $5.5 million in critical growth capital. We are thrilled to see rapid growth in our Investor Network — individuals, family offices, and other institutional investors. We’re just getting started — we look forward to many more years of supporting this important innovation ecosystem together. Please reach out if you’d like to learn more and get involved! [email protected]

01/20/2023

Engage Managing Director Kelly Prchal spoke with MinneInno about our Outlook for 2023. We continue to be excited by the opportunity to support early stage medtech teams.

Click below to read the article.

Twin Cities-based venture capital firms are bracing for a continuation of a market downturn in 2023, as the broader U.S. ecosystem anticipates declines in deal value and fundraising this year.

12/08/2022

Exciting news: Engage Venture Partners is proud to be the lead investor for VOCxi Health's seed funding round! We raised over $1.6 million in a Special Purpose Vehicle (SPV) with 39 individual and institutional investors from 10 states.

We’re thrilled to be supporting Ping Yeh, Randy Schiestl, Greg Sherwood, and Raia Finc as they develop revolutionary diagnostic breath sensor products for the early detection of chronic diseases, including lung cancer. We look forward to working with this amazing team as they build and scale.

"Fundraising is one of the most important efforts for a startup, and I am so pleased with how Engage led our development funding round. Their knowledge and thoughtful advice was extremely helpful as we approached our fundraising. Through their strong network of highly engaged investors, they contributed a significant portion of this first round, and we are thrilled to have Morgan Evans from Engage join our Board of Directors.” - Ping Yeh, CEO, VOCxi Health

To learn how you can support medtech innovation by participating in future Engage SPVs, please email [email protected].

11/01/2022

New Blog Post! Early Stage Medtech Investing: What To Look For

A quick and easy read reviewing some key criteria that we evaluate when we conduct due diligence on early-stage medtech companies.

If you'd like to learn more about our model or upcoming SPVs, please reach out at [email protected]

https://engagevp.com/news%2Bblog/f/early-stage-medtech-investing-what-to-look-for

By Kelly Prchal, Founder and Managing Director at Engage Venture Partners

10/13/2022

Engage Venture Partners is pleased to announce the completion of our second SPV — a Series A investment in Agitated Solutions, Inc.

Agitated Solutions is reimagining ultrasound contrast. Designed by a physician to improve workflow efficiency, the revolutionary Orbis™ microbubble generator delivers consistent, high-density bubbles with extended duration.

“I feel fortunate to have worked with Engage on our fundraise. The SPV model allows for collaboration on so many levels — it is incredibly founder- and investor-friendly. The Engage team and our new investors helped us get to the goal line to complete this important round of financing, which will fund the commercial launch of our first product and allow us to continue developing innovative new offerings.” - Morgan Evans, CEO, Agitated Solutions

Congratulations to Agitated Solutions on your successful round! We look forward to being involved in your ongoing innovation.

To learn more about investing in Engage's future SPVs, visit our website (http:engagevp.com) or email [email protected]

07/07/2022

Thanks to Carter Jones at the Minneapolis/St. Paul Business Journal (MSPBJ) for helping us tell the community a bit more about what makes our model so compelling. Let's connect so you can get "engaged" in our next deal! (email: [email protected])

Kelly Prchal

'It's kind of taking the world by storm in terms of capital raising,' Steve Sigmond, founder and managing director of Engage Venture Partners, said of the firm's special purpose vehicle approach to investing.